Adjuvant α-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma

Bone Marrow Transplantation

Volumn 22, Issue 7, 1998, Pages 639-643

  Byrne, J L ^a   Carter, G I ^a   Bienz, N ^a   Haynes, A P ^a   Russell, N H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Allogeneic transplantation; Interferon; Myeloma

Indexed keywords

ALPHA INTERFERON; CYTOKINE;

ADJUVANT THERAPY; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

EID: 0031765509     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701403     Document Type: Article

References (17)

1. Gahrton G, Ture S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1322.
2. Gahrton G, Ture S, Ljungman P et al for the European Group for Bone and Marrow Transplantation. Allogeneic bone marrow transplantation in multiple myeloma. New Engl J Med 1991; 325: 1267-1270.
3. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic bone marrow transplantation for multiple myeloma. An analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
4. Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Br J Haematol 1996; 92: 251-254.
5. Russell N, Miflin G, Stainer C et al. Allogeneic bone marrow transplantation for multiple myeloma. Blood 1997; 89: 2610-2611.
6. Grander D, Sangfelt O, Erikson S. How does interferon exert its cell growth inhibitory effect? Eur J Haematol 1997; 59: 129-135.
7. Avvisati G, Petrucci M. Is alpha-interferon in multiple myeloma worthwhile? Stem Cells 1995; 13: 106-113.
8. Powles R, Raje N, Cunningham D et al. Maintenance therapy for remission in myeloma with intron-A following high-dose melphalan and either an autologous bone marrow transplant or peripheral blood stem cell rescue. Stem Cells 1995; 13: 114-117.
9. Higano C, Raskind W, Singer J. Use of alpha-interferon for the treatment of relapse of chronic myelogenous leukaemia in chronic phase after allogeneic bone marrow transplantation. Blood 1992; 80: 1437-1442.
10. Tricot G, Vesole D, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
11. Bertz H, Burger J, Kinzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-vers us-myeloma effect. Leukemia 1997; 11: 281-283.
12. Collins R, Shpilberg O, Drobyski W et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic BMT. J Clin Oncol 1997; 15: 433-444.
13. Gressler V, Weinkauff R, Franklin W, Golomb H. Modulation of the expression of major histocompatibility antigens on splenic hairy cells - differential effect upon in vitro treatment with alpha-2b-interferon, gamma-interferon and interleukin-2. Blood 1988; 72: 1048-1053.
14. Klingmann H, Phillips G. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1994; 8: 73-81.
15. Samson D, Volin L, Schanz U et al. Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT. Bone Marrow Transplant 1996; 17: 759-762.
16. Bird JM, Russell NH, Samson D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant 1993; 12: 651-654.
17. Reece DE, Shepherd JD, Klingemann HG et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 117-123.